Dexamethasone for Cerebral Toxoplasmosis

Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with proper treatment and 80% without it. The fatality mainly due to the brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given, adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains unclear. Moreover, its safety in immunodeficiency cases is still debatable.

NCT Number	NCT04341155
Lead Sponsor	Universitas Padjadjaran
Conditions	Toxoplasmosis, Cerebral
Enrollment	138 participants
Start Date	2021-04-16
Primary Completion	2025-04 (estimated)
Study Completion	2025-07 (estimated)
Updated on ClinicalTrials.gov	2024-07-03